Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Wendy B. London"'
Autor:
Rajen Mody, Barry L. Shulkin, Mildred Felder, Paul M. Sondel, Howard M. Katzenstein, Wendy B. London, Shahab Asgharzadeh, Alice L. Yu, Julia Glade-Bender, Rochelle Bagatell, Marguerite T. Parisi, Arlene Naranjo, Jennifer Birstler, Fan F Zhang, Mitchell B. Diccianni, Jacquelyn A. Hank, Julie R. Park, Sabah-E-Noor Servaes, John M. Maris
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 19
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 19
PURPOSE The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with relapsed/refractory neuroblastoma in the randomized Children’s Oncology Gr
Autor:
Natia Esiashvili, Edward F. Attiyeh, Peter Mattei, Susan L. Cohn, Wendy B. London, Arlene Naranjo, Araz Marachelian, Sheena C. Tenney, Mary Lou Schmidt, John M. Maris, E. Stanton Adkins, Katherine K. Matthay, Julie M. Gastier-Foster, Howard M. Katzenstein, Margaret H. Collins, Clare J. Twist, Julie R. Park, Michael H. Handler, Hiroyuki Shimada, Elizabeth Wagner, Michael D. Hogarty
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 34
J Clin Oncol
J Clin Oncol
PURPOSE The primary objective of the Children’s Oncology Group study ANBL0531 (ClinicalTrials.gov identifier: NCT00499616 ) was to reduce therapy for subsets of patients with intermediate-risk neuroblastoma using a biology- and response-based algor
Autor:
Wendy B. London, Barry L. Shulkin, Arlene Naranjo, John M. Maris, Steven D. Gillies, Julie R. Park, Hank Ja, Marguerite T. Parisi, Paul M. Sondel, Sabah Servaes, Collin Van Ryn, Jacek Gan, Suzanne Shusterman, Hiroyuki Shimada
Publikováno v:
Clinical Cancer Research. 25:6044-6051
Purpose: Combining anti-GD2 (disialoganglioside) mAb with GM-CSF, IL2, and isotretinoin is now FDA-approved for high-risk neuroblastoma minimal residual disease (MRD) therapy. The humanized anti-GD2 antibody conjugated to IL2 (hu14.18-IL2) has clinic
Autor:
Holly J. Meany, Cody J. Peer, William D. Figg, Wendy B. London, Suzanne Shusterman, Elizabeth Fox, Carlos Rodriguez-Galindo, Brigitte C. Widemann, O Morgan Hall, AeRang Kim, Emily Stern, Rochelle Bagatell, Nalini Jayaprakash, Jeffrey S. Dome, Pamela S. Hinds, Jane E. Minturn, Tristan M. Sissung
Publikováno v:
Pediatric Blood & Cancer. 68
Background Sorafenib,an orally bioavailable, multitarget tyrosine kinase inhibitor, and irinotecan, a topoisomerase I inhibitor, have demonstrated activity in pediatric and adult malignancies. We evaluated the toxicity, pharmacokinetic (PK), and phar
Autor:
Sheena C. Tenney, Mary Lou Schmidt, John M. Maris, Katherine K. Matthay, Clare J. Twist, Wendy B. London, E. Stanton Adkins, Peter Mattei, Susan L. Cohn, Julie R. Park, Holly J. Meany, Hiroyuki Shimada, Arlene Naranjo
Publikováno v:
Journal of Clinical Oncology. 37:115-124
Purpose Infants with stage 4S neuroblastoma usually have favorable outcomes with observation or minimal chemotherapy. However, young infants with symptoms secondary to massive hepatomegaly or with unfavorable tumor biology are at high risk of death.
Autor:
Wendy B. London, Susan L. Cohn, Ulrike Pötschger, Michael D. Hogarty, Takehiko Kamijo, Shifra Ash, Frank Berthold, Dongjing Guo, Andrew D.J. Pearson, Ruth Ladenstein, Lucas Moreno, Daniel A. Morgenstern, Claudia Pasqualini, Dominique Valteau-Couanet, Meredith S. Irwin
Publikováno v:
Pediatric Blood & Cancer. 68
Long-term outcome remains poor for children with high-risk neuroblastoma (five-year overall survival [OS] ∼50%). Our objectives were to (a) identify prognostic biomarkers and apply them in a nomogram to identify the subgroup of ultra-high-risk pati
Autor:
Julie R. Park, Sheena C. Tenney, Katherine K. Matthay, Wendy B. London, Michael D. Hogarty, Jessica A. Panzer, Pedro A. de Alarcon, Arlene Naranjo, Susan L. Cohn, John M. Maris
Publikováno v:
The lancet child & adolescent health
Summary Background No clinical trial has been done for patients with neuroblastoma-associated opsoclonus myoclonus ataxia syndrome (OMA) and existing treatment is based on case reports and small retrospective studies. We aimed to assess OMA response
Autor:
Rochelle Bagatell, Julia L. Glade Bender, Wendy B. London, Barry L. Shulkin, Alice L. Yu, Rajen Mody, Arlene Naranjo, Mitchell B. Diccianni, John M. Maris, Julie R. Park, Paul M. Sondel, Sabah Servaes, Collin Van Ryn, Marguerite T. Parisi
Summary Background Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomide has activity in these patients, and its acceptable toxicity profile makes it an excellent backbone for stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1d3d6b77ef7e9a87221c84014791cc8
https://europepmc.org/articles/PMC5527694/
https://europepmc.org/articles/PMC5527694/
Autor:
Daphne A. Haas-Kogan, Wendy B. London, Stephan A. Grupp, Stephen S. Roberts, John M. Maris, Jacqueline M. Kraveka, Stephan D. Voss, Lisa Diller, Julie R. Park, Arlene Naranjo, Sheena C. Tenney, Susan G. Kreissman, Michael D. Hogarty, Peter J. Shaw, James Duncan Geiger, Susan L. Cohn, John J. Doski
Publikováno v:
JAMA. 322:746
Importance Induction chemotherapy followed by high-dose therapy with autologous stem cell transplant and subsequent antidisialoganglioside antibody immunotherapy is standard of care for patients with high-risk neuroblastoma, but survival rate among t
Autor:
Gudrun Schleiermacher, Akira Nakagawara, Thorsten Simon, Susan L. Cohn, Daniel A. Morgenstern, Meredith S. Irwin, Hiroyuki Shimada, Samuel L. Volchenboum, Andrew D.J. Pearson, Derek Stephens, Katherine K. Matthay, Wendy B. London
Publikováno v:
European journal of cancer (Oxford, England : 1990). 65
Neuroblastoma is a childhood cancer with remarkably divergent tumour behaviour and the presence of metastatic disease is a powerful predictor of adverse outcome. However, the importance of the involvement of specific metastatic sites or overall metas